Evommune, Inc. (EVMN) stock
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
$7.02−0.08 (-1.13%)
Close on Nov 17, 2026Market cap $254.77MP/E –Yield –
Evommune revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Evommune's revenue for the twelve months ending Sep 30, 2026 was $0, down 100.0% year over year. For fiscal 2025 it was $13.00M, up 85.7% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.00M | +85.7% |
| FY2024 | Dec 31, 2024 | $7.00M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0 | -100.0% |
| Q2 FY2026 | Jun 30, 2026 | $0 | – |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $0 | – |
| Q3 FY2025 | Sep 30, 2025 | $10.00M | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $3.00M | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
See a number that looks wrong?